Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc.
Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of the ever-evolving coronavirus. Those doses can be used in adults and children as young as 6 months.
Friday, the Food and Drug Administration gave the OK to the updated Novavax formula, too — and those shots are open to anyone 12 and older.
While most Americans have some degree of immunity from prior infections or vaccinations or both, that protection wanes. Despite this summer's wave, winter surges of COVID-19 tend to be worse and health officials are urging Americans to get one of the vaccine options this fall.
Novavax makes a protein-based vaccine mixed with an immune booster, a different technology than Pfizer and Moderna’s so-called mRNA vaccines.
This year there’s another slight difference in the formulations. The Pfizer and Moderna recipes are tailored to a virus subtype called KP.2. The Novavax formula targets its parent strain, called JN.1. The FDA considers both closely enough related to currently circulating strains to offer cross-protection.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
